ProQR Therapeutics N.V. (PRQR)
| Market Cap | 261.07M +28.2% |
| Revenue (ttm) | 15.73M -30.5% |
| Net Income | -52.45M |
| EPS | -0.50 |
| Shares Out | 141.12M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 600,282 |
| Open | 1.900 |
| Previous Close | 1.860 |
| Day's Range | 1.840 - 1.920 |
| 52-Week Range | 1.330 - 3.100 |
| Beta | 0.03 |
| Analysts | Strong Buy |
| Price Target | 8.25 (+345.95%) |
| Earnings Date | Aug 13, 2026 |
About PRQR
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metab... [Read more]
Financial Performance
In 2025, ProQR Therapeutics's revenue was 16.35 million, a decrease of -16.36% compared to the previous year's 19.55 million. Losses were -42.18 million, 51.9% more than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for PRQR stock is "Strong Buy." The 12-month stock price target is $8.25, which is an increase of 345.95% from the latest price.
News
ProQR Announces Second Quarter 2026 Operating and Financial Results
LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative R...
ProQR Therapeutics Earnings release: Q2 2026
ProQR Therapeutics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
ProQR Therapeutics registers to sell 3.03M ordinary shares for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 3.03M ordiary shares. The company is not selling any shares under…
ProQR Therapeutics Registration statement: Registration filing
ProQR Therapeutics filed a registration statement on July 6, 2026, providing details about a securities offering with the SEC.
ProQR Therapeutics price target lowered to $10 from $14 at Raymond James
Raymond James lowered the firm’s price target on ProQR Therapeutics (PRQR) to $10 from $14 and keeps a Strong Buy rating on the shares. Based on the thesis that early…
ProQR Therapeutics price target lowered to $10 from $11 at JonesResearch
JonesResearch analyst Catherine Novack lowered the firm’s price target on ProQR Therapeutics (PRQR) to $10 from $11 and keeps a Buy rating on the shares. The firm cites the company’s…
ProQR Therapeutics price target lowered to $3 from $4 at Chardan
Chardan analyst Keay Nakae lowered the firm’s price target on ProQR Therapeutics (PRQR) to $3 from $4 and keeps a Buy rating on the shares. The company reported target engagement…
ProQR Therapeutics Slides: Conference presentation
ProQR Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 25, 2026.
ProQR Therapeutics prices 27.62M shares at $1.81 in registered direct offering
ProQR Therapeutics (PRQR) announced the pricing of an underwritten registered direct offering of 27,624,310 ordinary shares at an offering price of $1.81 per share (the “Offering Price”), for total gr...
ProQR Therapeutics announces positive Phase 1 data for AX-0810
ProQR Therapeutics (PRQR) announced positive target engagement data from its ongoing Phase 1 clinical study evaluating AX-0810, the company’s first investigational Axiomer RNA editing oligonucleotide,...
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
LEIDEN, Netherlands and CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a clinical-stage biotechnology company dedicated to changing lives through...
ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR or the Company), a clinical-stage biotechnology company dedicated to changing li...
ProQR Announces First Quarter 2026 Operating and Financial Results
AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indication Pipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDU...
ProQR Therapeutics Earnings release: Q1 2026
ProQR Therapeutics released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative R...
ProQR Therapeutics management to meet with Cantor Fitzgerald
Meeting to be held in New York on April 13 and in Boston on April 14 hosted by Cantor Fitzgerald.
ProQR Therapeutics management to meet with Oppenheimer
Meeting to be held on April 9-10 hosted by Oppenheimer.
ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies ba...
ProQR Therapeutics Transcript: Status update
Multiple clinical programs are advancing, including AX-0810 for biliary atresia and AX-0811 with improved editing efficiency. AI-driven discovery and strategic partnerships are accelerating pipeline progress, with a strong focus on both liver and CNS indications and a financial runway into mid-2027.
ProQR Therapeutics Press release: Status update
ProQR Therapeutics issued a press release on April 8, 2026, disclosing material business information to investors.
ProQR Therapeutics Slides: Status update
ProQR Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on April 8, 2026.
ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board
ProQR and Ginkgo Bioworks to collaborate on autonomous lab high throughput data generation to support ProQR's AI-enabled drug discovery for Axiomer™ ProQR establishes AI Advisory Board with leaders fr...
ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.